Ionis Pharmaceuticals Inc
$ 85.45
1.00%
24 Feb - close price
- Market Cap 13,703,034,000 USD
- Current Price $ 85.45
- High / Low $ 85.47 / 83.45
- Stock P/E N/A
- Book Value 3.84
- EPS -1.61
- Next Earning Report 2026-02-25
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.06 %
- ROE -0.40 %
- 52 Week High 86.74
- 52 Week Low 23.95
About
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapies in the United States. The company is headquartered in Carlsbad, California.
Analyst Target Price
$91.63
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-25 | 2025-10-29 | 2025-07-30 | 2025-05-05 | 2025-02-19 | 2024-11-06 | 2024-08-01 | 2024-05-07 | 2024-02-21 | 2023-11-02 | 2023-08-09 | 2023-05-03 |
| Reported EPS | 0 | -0.8 | 0.7 | -0.9245 | -0.4304 | -0.95 | -0.45 | -0.98 | -0.06 | -1.03 | -0.6 | -0.87 |
| Estimated EPS | -1.33 | -1.22 | -0.24 | -1.01 | -0.8444 | -1.16 | -0.92 | -1.05 | -0.83 | -1.04 | -0.9 | -0.91 |
| Surprise | 1.33 | 0.42 | 0.94 | 0.0855 | 0.414 | 0.21 | 0.47 | 0.07 | 0.77 | 0.01 | 0.3 | 0.04 |
| Surprise Percentage | 100% | 34.4262% | 391.6667% | 8.4653% | 49.0289% | 18.1034% | 51.087% | 6.6667% | 92.7711% | 0.9615% | 33.3333% | 4.3956% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-25 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -1.32 |
| Currency | USD |
Previous Dividend Records
| Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | None | None | None | None | None | None | None | None | None | None |
| Amount | $0.186 | $0.11 | $0.11 | $0.11 | $0.11 | $0.11 | $0.11 | $0.11 | $0.11 | $0.11 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: IONS
2026-02-24 08:53:14
Ionis Pharmaceuticals (NASDAQ:IONS) is identified as a strong candidate for a potential breakout, exhibiting a high Technical Rating of 9 out of 10 and a Setup Quality Rating of 9 out of 10. The stock shows a robust uptrend with positive short and long-term trends, pricing above all key moving averages, and outperforming 95% of stocks over the past year. This analysis suggests IONS is setting up for a move higher, with a sample trading plan provided to illustrate potential entry and exit points.
2026-02-22 12:46:40
The first patient has been dosed in the Phase 3 REVEAL study for ION582, a treatment for Angelman Syndrome. This marks a significant milestone in advancing potential therapies for this neurodevelopmental disorder. Further details about the study design or expected timeline were not provided in this brief announcement.
2026-02-22 08:16:55
AstraZeneca has discontinued clinical trials for AZD8233, an RNA-based drug for heart disease developed with Ionis Pharmaceuticals, because it did not meet pre-specified efficacy criteria. Although the drug reduced "bad cholesterol" more than an existing treatment, Novartis' Leqvio, its inconvenience and commercial considerations likely played a role in the decision. This marks a setback for the decade-long collaboration between AstraZeneca and Ionis, though they recently announced success with another rare disease drug.
2026-02-21 08:43:21
Aberdeen Group plc significantly reduced its stake in Ionis Pharmaceuticals ($IONS) by 78.4% in the third quarter, selling 318,770 shares and retaining 87,924 shares valued at $5.75 million. This comes amidst substantial insider selling, with CEO Brett Monia and EVP Eric Swayze selling shares totaling approximately $7 million, contributing to insiders selling 481,356 shares worth about $38.99 million in the last 90 days. Despite this selling activity, analysts maintain a "Moderate Buy" consensus rating with an average price target of $86.95, and several firms have recently raised their price targets for the stock.
2026-02-20 16:32:27
Ionis Pharmaceuticals Inc. (IONS) has terminated its early-stage "Hero" study, which investigated the safety and pharmacokinetics of ION269 for Down syndrome patients at risk of Alzheimer’s disease. The trial was a Phase 1b study designed to assess a single dose of the experimental drug delivered into the spinal fluid. While a setback for Ionis's Alzheimer's endeavors in this specific demographic, the company's broader RNA-based pipeline remains a focus, and investors will be looking for reasons behind the termination and its implications for Ionis's market positioning.
2026-02-17 20:27:22
Ionis Pharmaceuticals, Inc. announced a change in the start time for its fourth quarter and full year 2025 financial results webcast. Originally scheduled for 11:30 a.m. Eastern Time, the webcast will now be held at 8:30 a.m. Eastern Time on Wednesday, February 28, 2026. The date of the call remains unchanged, and a replay will be available for a limited time at the same web address.
